Abiomed, Inc.
0H7S.L
London Stock Exchange381.02
USD
+0.30
- -
Abiomed, Inc.
0H7S.L
(London Stock Exchange)
Recent
price
381.02
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Abiomed, Inc. Abiomed Inc (Ticker: 0H7S.L), a leader in minimally invasive cardiac support technologies headquartered in Danvers, Massachusetts and founded in 1981, develops, manufactures and markets advanced heart recovery systems as a subsidiary of Johnson & Johnson MedTech following its $16.6 billion acquisition in December 2022; the company offers the flagship Impella heart pump platform, including Impella CP heart pumps approved by the U.S. Food and Drug Administration for high-risk percutaneous coronary intervention and acute myocardial infarction cardiogenic shock, as well as related accessories, clinical support services encompassing on-site, on-call and online patient management, and educational training programs for healthcare professionals to optimize outcomes in heart failure treatment. Abiomed operates globally with primary segments in the United States, Europe and Japan, serving cardiologists, hospitals and cardiac care centers focused on enabling native heart recovery through circulatory and oxygenation support rather than permanent replacement. In recent developments, the company integrated into Johnson & Johnson MedTech with a rebranded identity effective January 2025 while retaining the Impella product line and Abiomed service branding, highlighted new Impella advancements and long-term survival data at TCT 2025 and ACC.25 conferences, and addressed device controller issues through targeted recalls and design enhancements in 2025 to maintain product reliability.